Hamish Innes
Biographic Data
| ID | 7447080 |
|---|---|
| NAME | Hamish Innes |
| GIVEN NAMES | Hamish |
| FAMILY NAME | Innes |
| SIGNATURE | INNES H |
| AFFILIATIONS | Health Protection Scotland |
| ORCID | 0000-0003-0565-1083 |
| VERIFIED | No |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 5 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2011 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Pharmacological treatments for alcohol dependence
Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era
Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy
Seven years have elapsed since the Scottish Government launched its Hepatitis C Action Plan - a Plan to improve services to prevent transmission of infection, particularly among people who inject drugs (PWID), identify those infected and ensure those infected receive optimal treatment. The Plan was underpinned by industrial scale funding (around £100 million, in addition to the general NHS funding, will have been invested by 2015), and a web of a…
Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow
P2-122 Response and predictors of response, to pegylated interferon and ribavirin for chronic hepatitis C patients in Scotland
Introduction It is not clear what proportion of HCV (hepatitis C virus) patients attain a sustained viral response (SVR) when treated with pegylated interferon and ribavirin combination therapy outside randomised clinical trials (RCTs). Secondly, pre-treatment factors available in routine clinical settings that are predictive of SVR (the optimal treatment outcome) are not known. Methods HCV clinical databases from nine Scottish treatment clinics …
No prominent works on this page.
P2-122 Response and predictors of response, to pegylated interferon and ribavirin for chronic hepatitis C patients in Scotland
Introduction It is not clear what proportion of HCV (hepatitis C virus) patients attain a sustained viral response (SVR) when treated with pegylated interferon and ribavirin combination therapy outside randomised clinical trials (RCTs). Secondly, pre-treatment factors available in routine clinical settings that are predictive of SVR (the optimal treatment outcome) are not known. Methods HCV clinical databases from nine Scottish treatment clinics …
Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow
Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy
Seven years have elapsed since the Scottish Government launched its Hepatitis C Action Plan - a Plan to improve services to prevent transmission of infection, particularly among people who inject drugs (PWID), identify those infected and ensure those infected receive optimal treatment. The Plan was underpinned by industrial scale funding (around £100 million, in addition to the general NHS funding, will have been invested by 2015), and a web of a…
Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era
Pharmacological treatments for alcohol dependence
Hepatitis C virus research (4 works) · Medicine (4 works) · Hepatitis C (3 works) · HIV, Drug Use, Sexual Risk (3 works) · Virus (3 works) · Environmental health (2 works) · Hepatitis C virus (2 works) · Immunology (2 works) · Internal Medicine (2 works) · Liver Disease Diagnosis and Treatment (2 works)